Rare Sugars: Metabolic Effects and Mechanisms of Action – A Scoping Review

What this review gives you

You don't need another review that tells you rare sugars are interesting. You need to know what the data actually support. This paper does that.

The review, published in the British Journal of Nutrition (DOI: 10.1017/S0007114521003524), looked at the current science on rare sugars. The authors focused on D-allulose and D-tagatose. They grouped the potential health benefits into three themes: glycemic control, body composition, and cardiovascular disease. That grouping helps you sort where evidence is solid and where it's still thin.

Why rare sugars matter for product developers

Rare sugars are not just bulk sweeteners. They may change how the body handles glucose and fat. For a formulator, that opens the door to functional products. But claims require evidence. This scoping review maps the evidence and shows you what is already tested in humans.

The most studied molecules are D-allulose and D-tagatose. Both are rare sugars. The review did not add new clinical data. Instead, it took stock of the human trials and mechanistic studies already published. That makes it a practical starting point for product development decisions.

How the review was built

A scoping review goes beyond a simple literature search. It sets boundaries around a topic and pulls together all relevant research. The authors examined the metabolic impact of rare sugars and looked at the mechanisms behind those effects. The review then sorted the evidence into the three outcome areas that matter to product developers.

The review classified evidence by rare sugar type and by outcome. That is useful because allulose and tagatose are often lumped together. They are different molecules, and the review keeps them distinct.

Key findings from the human evidence

The human data point to a clear pattern. When D-allulose or D-tagatose is ingested alongside carbohydrates, the blood glucose rise is lower in people with hyperglycemia. That is the most consistent finding in the review.

Body composition data were more specific. In one human trial, taking 14 grams of D-allulose per day produced modest but significant changes. BMI dropped by 0.38 kg/m². Body fat percentage dropped by 0.74%. Those numbers are not dramatic. They are real changes from a single daily dose.

Rare sugar	Main evidence in humans	Observed effect
D-allulose (PSI)	Co-ingested with carbohydrates	Lower post-meal glucose rise in hyperglycemia; daily 14 g modestly reduced BMI and body fat
D-tagatose (TAG)	Co-ingested with carbohydrates	Lower post-meal glucose rise in hyperglycemia

Notice what the table does not show. There is no strong evidence here that tagatose matches allulose for body composition. The review groups tagatose under glycemic control. If you are choosing between the two, match the ingredient to the claim you want to support.

What this means for manufacturers

Start with the glucose data. The evidence that allulose and tagatose blunt post-meal glucose spikes is consistent enough to guide product concepts. Think beverages, bars, or tabletop sweeteners used with high-carb meals. The target audience could be people with hyperglycemia or those managing blood sugar.

The body composition data are thinner but still valuable. The 14-gram dose is not huge. It is realistic for a daily serving. A product containing 14 grams of allulose is feasible in a beverage or a syrup format. You can already build a product around that dose.

The cardiovascular theme is part of the review's framework, but the evidence included here is more indirect. Do not treat it as a claim yet. The mechanisms may exist, but the review does not give you a number to work with.

Stability and compatibility are your next questions. You will need to test both in your own system. The clinical data tells you where to aim. Your bench trials will tell you if the product works.

Questions formulators ask

Is PSI the same as allulose? In this paper, PSI refers to psicose. D-allulose is also known as D-psicose. They are the same molecule. If you see PSI in a study, you are reading about allulose.

Can I make a health claim based on this review? No. A scoping review is not regulatory evidence. It helps you decide which ingredient to investigate and which endpoints to measure. You still need your own human trial or an approved claim framework.

Does tagatose work as well as allulose for weight control? The review does not say that. It reports body composition data for allulose. Tagatose appears mainly in the glycemic control findings. Use it where that effect fits.

The rare sugar field is moving fast, but this paper gives you a stable view of what happened in the human studies. The glycemic effect is the strongest point. The body composition effect is modest but measurable. The rest is still open for investigation. That is a good place to start your own formulation work.